SGLT2-Inhibition in Patients With Alport Syndrome
Open Access
- 24 September 2024
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 9 (12) , 3490-3500
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Efficacy of Dapagliflozin in Adult Autosomal Recessive Alport SyndromeKidney International Reports, 2022
- Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical ConsiderationsKidney International Reports, 2022
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndromeKidney International, 2020
- Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults–an update for 2020Pediatric Nephrology, 2020
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressureDiabetologia, 2018
- Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working GroupKidney International, 2018
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibitionDiabetologia, 2016
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltrationDiabetologia, 2014
- Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritisPediatric Nephrology, 2000